Cite
Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis
MLA
Juyoun Jin, et al. “Anticancer Activity of TTAC-0001, a Fully Human Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2/KDR) Monoclonal Antibody, Is Associated with Inhibition of Tumor Angiogenesis.” MAbs, vol. 7, no. 6, Sept. 2015, pp. 1195–204. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....371574904a09f88c629ba6c1579d30ff&authtype=sso&custid=ns315887.
APA
Juyoun Jin, Sang Ryeol Shim, Donggeon Kim, Younggeon Jin, Heekyoung Yang, Sung Woo Kim, Jin-San Yoo, Sang Hoon Lee, Do-Hyun Nam, Jinsang Yoo, Kyeung Min Joo, & Weon Sup Lee. (2015). Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. MAbs, 7(6), 1195–1204.
Chicago
Juyoun Jin, Sang Ryeol Shim, Donggeon Kim, Younggeon Jin, Heekyoung Yang, Sung Woo Kim, Jin-San Yoo, et al. 2015. “Anticancer Activity of TTAC-0001, a Fully Human Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2/KDR) Monoclonal Antibody, Is Associated with Inhibition of Tumor Angiogenesis.” MAbs 7 (6): 1195–1204. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....371574904a09f88c629ba6c1579d30ff&authtype=sso&custid=ns315887.